<DOC>
	<DOCNO>NCT02511028</DOCNO>
	<brief_summary>Background : - Contrast agent help thing show well magnetic resonance imaging ( MRI ) scan . Researchers want see drug ferumoxytol good contrast agent . They want determine cause prolong MRI change brain see help identify inflammation multiple sclerosis Objective : - To learn ferumoxytol use image inflammation multiple sclerosis ( MS ) . Eligibility : - Adults age 18 70 MS. - Healthy volunteer age 18 70 . Design : - Participants 5 clinic visit 6 month . - Participants screen medical history , neurological exam , blood draw . Full clinical measure obtain . - Participants 7 tesla brain MRI scan may include gadolinium contrast agent . The MRI metal cylinder strong magnetic field . The participant lie table slide cylinder . - During visit 2 , ferumoxytol give catheter ( thin plastic tube ) insert needle vessel arm . &lt; TAB &gt; - Participants 7 tesla MRI scan brain.. - At next 3 clinic visit , participant 7 tesla brain MRI blood drawn . The MRIs may include gadolinium . - Participants may full neurologic exam visit . At final visit , full clinical measure obtain . - Participants may MRI scan 6-month MRI show ferumoxytol still brain .</brief_summary>
	<brief_title>In Vivo Characterization Inflammation With Ferumoxytol , Ultrasmall Superparamagnetic Iron Oxide Nanoparticle , 7 Tesla Magnetic Resonance Imaging</brief_title>
	<detailed_description>Objective The goal pilot study ( 1 ) demonstrate safety ferumoxytol , United States Food Drug Administration ( FDA ) approve drug use treatment iron deficiency anemia , contrast agent brain magnetic resonance imaging ( MRI ) , determine lack long-term signal change healthy volunteer ( HV ) people multiple sclerosis ( MS ) ; ( 2 ) determine ferumoxytol enhancement detect MS lesion 7-tesla ( T ) MRI ; ( 3 ) examine spatial temporal enhancement pattern ferumoxytol compare pattern see gradient-echo image gadolinium contrast MS lesion . Study population Up 10 HVs 10 participant MS recruit study . Design Participants undergo series brain MRIs 7 T scanner . MRI ( baseline ) 0-8 hour , 24-96 hour , 1 month , 6 month follow ferumoxytol administration . Outcome measure The primary outcome measure change gradient-echo T2-weighted signal ( derive MR sequence sensitive paramagnetic agent iron ) globus pallidus , know brain iron reservoir , 6 month follow ferumoxytol administration . Thus , determine ferumoxytol induces long-lasting brain signal intensity change HV MS . Secondary outcome measure : ( 1 ) number , location , qualitative morphology ferumoxytol , gradient-echo phase , gadolinium-enhanced MS lesion lesion change time ; ( 2 ) quantitative estimate change iron concentration determine R2 ( = 1/T2 ) relaxation rate within MS lesion , normal appear white matter , normal appear gray matter , iron-rich region within brain ferumoxytol injection .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>INCLUSION CRITERIA : HEALTHY VOLUNTEER INCLUSION CRITERIA age 18 70 ( inclusive ) able give inform consent brain MRI within 2 year study enrollment show clinically significant abnormality , judgment boardcertified NIHcredentialed neuroradiologist PATIENT INCLUSION CRITERIA age 18 70 , inclusive able give inform consent diagnosis multiple sclerosis accord revise McDonald Criteria EXCLUSION CRITERIA : GENERAL EXCLUSION CRITERIA : screening lab demonstrate value hepatic renal function level range normal , include AST , ALT , bilirubin , alkaline phosphatase , creatinine , eGFR evidence polycythemia vera hemoglobin level 1 standard deviation NIH laboratory normal level iron overload syndrome , include hemochromatosis , subject evidence iron overload baseline ferritin level great 370 ng/ml percent saturation transferrin level great 40 % . previous current alcohol and/or substance abuse per medical history medical record medical contraindication MRI ( e.g. , nonorganic implant device cardiac pacemaker infusion pump metallic implant , object , body piercings MRIcompatible remove ) psychological contraindication MRI ( e.g. , claustrophobia ) , assessed time medical history collect pregnancy current breastfeeding report history clinically significant impaired hearing , people impair hear increase risk soundinduced damage MRI scanner know allergy dextran drug contain iron salt previous history severe allergic reaction , anaphylaxis , drug clinically significant medical neurological disorder , judgment investigator might expose patient undue risk harm confound study outcomes prevent participant complete study ; example condition include limited diagnosis certain type cancer , cardiopulmonary condition congestive heart failure , uncontrolled hypertension ADDITIONAL PATIENT EXCLUSION CRITERION : 4 gadoliniumenhancing lesion screen scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 6, 2017</verification_date>
	<keyword>MRI</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>